Tadalafil Dosing Recommendations
For erectile dysfunction, start with tadalafil 10 mg as needed or 2.5 mg daily; for pulmonary arterial hypertension, use 40 mg once daily. 1
Erectile Dysfunction Dosing
As-Needed Regimen
- Starting dose: 10 mg taken prior to anticipated sexual activity 1
- Titrate based on response:
- Increase to 20 mg if inadequate response
- Decrease to 5 mg if side effects occur
- Maximum frequency: once per day
- Effective window: up to 36 hours after dosing 1
Once-Daily Regimen
- Starting dose: 2.5 mg taken at the same time daily, regardless of sexual activity timing 1
- May increase to 5 mg daily based on efficacy and tolerability 1
- This regimen provides continuous therapeutic effect without timing sexual activity 2
The AUA guideline strongly recommends dose titration to optimize efficacy 3, and both regimens show similar overall efficacy across most patient populations 2.
Pulmonary Arterial Hypertension Dosing
The recommended dose is 40 mg once daily 4. This is the evidence-based dose from pivotal trials showing improvements in 6-minute walk distance, functional class, and hemodynamic parameters 4, 5. Recent systematic reviews confirm tadalafil 40 mg demonstrates marked improvements in pulmonary vascular resistance, particularly when combined with endothelin receptor antagonists 6.
Dose Adjustments in Special Populations
Renal Impairment
For As-Needed Dosing:
- CrCl 30-50 mL/min: Start with 5 mg, maximum 10 mg once every 48 hours 1
- CrCl <30 mL/min or hemodialysis: Maximum 5 mg once every 72 hours 1
For Once-Daily Dosing:
- CrCl <30 mL/min or hemodialysis: Not recommended for ED 1
- CrCl 30-50 mL/min (for BPH/ED): Start with 2.5 mg, may increase to 5 mg 1
These restrictions exist because renal insufficiency approximately doubles systemic exposure 7. Hemodialysis does not significantly remove tadalafil 7.
Hepatic Impairment
For As-Needed Dosing:
- Mild-moderate (Child-Pugh A or B): Maximum 10 mg once daily 1
- Severe (Child-Pugh C): Not recommended 1
For Once-Daily Dosing:
Hepatic impairment has negligible effects on tadalafil pharmacokinetics in mild-moderate disease 7, but caution is warranted due to limited data.
Older Adults
No dose adjustment required based on age alone 1. Elderly patients (≥65 years) have 25% higher exposure, but this is not clinically significant 1, 7. In PAH trials, elderly patients showed similar efficacy and safety profiles to younger patients, with comparable improvements in 6-minute walk distance 8. However, consider greater medication sensitivity in some older individuals when initiating therapy 1.
Diabetes Mellitus
No dose adjustment needed 1. Patients with diabetes have approximately 19% lower exposure than healthy subjects, which is not clinically meaningful 1, 7. However, diabetic patients and post-prostatectomy patients have more severe baseline ED and may respond less robustly to PDE5 inhibitors 3.
Critical Prescribing Considerations
Contraindications
- Absolute contraindication with nitrates in any form 1
- When combining with alpha-blockers for ED, patients must be stable on alpha-blocker therapy first, and start tadalafil at the lowest dose 1
- Do not combine with alpha-blockers for BPH treatment 1
Common Pitfalls
The AUA guideline emphasizes that incorrect use accounts for many treatment failures 3. Ensure patients understand:
- Sexual stimulation is required for effect
- Avoid taking with large meals (though food doesn't affect absorption, timing matters for patient expectations)
- Allow adequate trial at each dose before declaring failure
Adverse Events
Most common: headache, dyspepsia, flushing, back pain, nasal congestion, myalgia 3. These follow a dose-response pattern and tend to decrease with continued use 8. Tadalafil has the lowest rates of flushing among PDE5 inhibitors 3.
Tablet Administration
Do not split tablets; take entire dose 1. May be taken without regard to food 1.